Sporadic reticulate acropigmentation of Kitamura on pale skin

from the areas treated showed a partial response, probably due to systemic effects of the rINF-a2a, so that they were subsequently treated intralesionally, too. Eight months after the start of therapy, we are still successfully treating with the same protocol other involved sites on the back; the affected areas previously treated are still free of lesions. Primary CBCL lymphomas represent a homogeneous group of lymphoproliferative diseases characterized by a slight tendency to extracutaneous spreading, a prompt response to radiotherapy which is considered the treatment of choice, and a good prognosis [5-71. In primary CBCL, systemic rINFa has been used in patients with extensive skin involvement or in the rare cases of systemic involvement [8,9]. Recently other authors have also reported interesting results with intralesional rINF-a2a (3-6 x lo6 IU, three times per week) [ 101. Intralesional administration has advantages over systemic treatment. Since this type of lymphoma rarely has distant localizations, intralesional therapy is sufficient to provide an optimal dose in the area of the lesions and can be successful also with low doses. Moreover intralesional administration limits the side effects and cost of IFN-therapy. In our patient, we observed a complete clinical remission in the areas treated in a relatively short time with intralesional low doses of rINFa2a (3 x lo6 IU weekly). In conclusion, the present results show that intralesional rIFN-a2a therapy is an effective alternative in primary cutaneous B-cell lymphoma, particularly in those cases in which radiotherapy is contraindicated. In our opinion, the dose necessary for an optimal therapeutic response is probably lower than that recently suggested by other authors [lo].